SLFN11 and Ewing sarcoma: Knockdown of SLFN11 has shown to result in decreased sensitivity to the DNA damaging cytotoxic agent trabectedin in preclinical liposarcoma and Ewing sarcoma (ES) models (Iwasaki et al. 2019) and decreased sensitivity to the PARPi talazoparib in small cell lung cancer (SCLC) cell lines (Lok et al. 2017).